Oncology Venture – for drug targeting 

Administering an ineffective oncology product to a cancer patient may be life threatening. An oncology product may cure one patient but maybe worthless or even harm another patient. Many oncology products only benefit a very small fraction of patients and there is no way to identify who will benefit. This forces oncologists to treat many patients in the blind, and if the fraction of benefiters is too low the product will not be used even if such a product may be the best product for certain patients.

“OV has a unique gene-tumor-technology to find out who will respond and who are resistant to a given anticancer drug – by avoiding treating patients who will not respond OV will put the product ahead of the cutting edge in competition. The difference in value between a product that works in 10% of the patients and 50% of patients is >100 fold. Drugs with response rates below 10% are abundant, but often impossible to develop without a key to its use.”

Oncology Venture will utilize the technology and acquire product rights or co-develop with drug owners where OV’s technology can predict efficacy.

Oncology Venture will acquire rights to five products and conduct focused small phase 2 trials in patients selected for high response rates. Within three years OV will sell or out-license the value enhanced drugs and create investor exit.

Oncology Venture’s versatile and broad technology is expected to be a game changer useful for a number of drugs, both marketed and under development.

Stock information

Latest (SEK)
High (SEK)
Low (SEK)

Updated on


Oncology Venture to evaluate Phase 3 product from Novartis

Press coverage from MedWatch media (Danish)
Press coverage from MedWatch media (Swedish)
Press release (English)


Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

See Press release
Läs pressmeddelande


Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP

See Press release
Läs pressmeddelande


OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010

See Press release
Läs pressmeddelande


2X Oncology obtains US IND for 2X-111 a Liposomal doxorubicin

See Press release
Läs pressmeddelande


The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP

See Press release
Läs pressmeddelande


2X Oncology Inc. presents at Jefferies Global Healtcare conference (live webcast)

Register and see the webcast


Berlingske Business: Interview with CEO of Oncology Venture

Read the article


Interview with OV and MPI in ‘Millionærklubben’

Listen to the radio program


Latest articles from MedWatch (Danish)

19 January 2017: Oncology Venture får europæisk stjernebevilling


VD Peter Buhl video presentation at Sedermeradagen in Copenhagen 23. March

See the Video


Oncology Venture secures seed financing for two SPVs & DRP Exclusivity



Oncology Venture: First DRP-positive breast cancer patient obtained reduction of tumor



Oncology Venture: Best Practice article on APO010

Download (In Danish only)


Presentation of OV by CEO Peter Buhl Jensen



Smallcap.se analysis of Oncology Venture



Peter Buhl Jensen talks about Oncology Venture – Radio24syv

Listen here – 10 July 2015
Listen here – 22 July 2015